FDA adds rare vision-loss warning to popular GLP-1 drugs

WASHINGTON (AP) — Popular weight loss drugs including Ozempic and Wegovy will carry a new warning about a possible rare side effect that can sometimes lead to permanent vision loss, U.S. health regulators announced Monday. The Food and Drug Administration said the risk will be added to the labeling of all GLP-1 drugs, the blockbuster medications used to treat obesity, diabetes and several other…

FDA adds rare vision-loss warning to popular GLP-1 drugs — The Independent · Left
FDA Orders New Vision Loss Warning for Ozempic, Wegovy, Mounjaro and Zepbound — Men's Journal · Left
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness — NBC News · Left
FDA Mandates New Eye Risk Warning on GLP-1 Drugs — Epoch Times · Right
US FDA orders new eye risk warnings for Ozempic, Zepbound — Salem Radio Network News · Right
FDA adds rare vision-loss warning to popular GLP-1 drugs — Troy Record
FDA adds rare vision-loss warning to popular GLP-1 drugs — Washington's Top News (WTOP)
FDA adds rare vision-loss warning to popular GLP-1 drugs — Winnipeg Free Press — Latest News
FDA adds rare vision-loss warning to popular GLP-1 drugs — KSTP-TV
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness — Upstract
US FDA orders new eye risk warnings for Ozempic, Zepbound — Upstract
US FDA orders new eye risk warnings for Ozempic, Zepbound — WNCY - 100.3 FM - Green Bay

Open True Mainstream to compare left, right, and center coverage